Ethinylestradiol/gestodene PSUSA ends in maintenance: what PV teams should check

What happened

On 5 November 2026 the EMA published the outcome of a periodic safety update report single assessment (PSUSA) for the ethinylestradiol/gestodene combination. The regulatory outcome is listed as maintenance of the marketing authorisations. The publication also includes a list of the nationally authorised products covered by the procedure.

The EMA entry in our records gives no more than that. It does not describe the safety questions assessed, the data period reviewed, or whether any product information wording was changed alongside the maintenance outcome. Those details are not yet known from the material we have, and teams should read the full published documents rather than rely on the headline result.

How to read a maintenance outcome

A PSUSA is the EU mechanism for assessing periodic safety update reports for medicines that share an active substance or combination, including products authorised only at national level. One assessment replaces separate national reviews, so the conclusion applies across the product family. The possible outcomes range from maintenance to variation, suspension or revocation of authorisations.

Maintenance means the benefit-risk balance has not led regulators to change the status of the authorisations. It does not necessarily mean nothing happens next. The published outcome and the product list are the working documents for follow-up. Marketing authorisation holders (MAHs) need to confirm that their products appear on the list and that their own safety databases and labelling match what was concluded.

The accompanying list of nationally authorised products matters in practice. For nationally authorised products, the outcome reaches the market through national implementation, so a QPPV office should know which local affiliates and licence partners are affected.

A routine week, with contrasts

The same day, the EMA published a second PSUSA outcome, for diethylamine-salicylate/escin, also ending in maintenance. Two maintenance results on one day is a reminder that most periodic assessments close without regulatory action. That is the expected outcome of a working surveillance system, not a sign that the process is empty.

Other records from the same week show a different kind of safety activity. The MHRA issued interim monitoring advice for Duvyzat (givinostat) after international reports of deaths in patients with Duchenne muscular dystrophy. It proposed more frequent ECG and electrolyte checks, with implementation subject to an ongoing independent review. The MHRA notes that no deaths have been reported in the UK. That is a fast, signal-driven response and works on a very different timescale from a scheduled PSUSA.

For PV teams the contrast is useful. Periodic assessments are a structured check on products with a long track record. Interim measures like the Duvyzat advice show how quickly a regulator can act on emerging information. A good PV system has to handle both, and the periodic cycle should not be allowed to substitute for continuous signal detection.

Who is affected and what sits alongside

The immediate audience is MAHs and QPPVs responsible for ethinylestradiol/gestodene products, along with national regulatory affairs staff who handle implementation. Teams covering diethylamine-salicylate/escin have a parallel, if separate, outcome to review.

Quality and PV functions also have an adjacent task. The EMA published a questions-and-answers document for MAHs and applicants on the CHMP opinion in the nitrosamine impurities referral under Article 5(3), reference EMEA-H-A5(3)-1490. This is a quality topic rather than a PSUSA matter, but it lands on the same desks. Companies with oral products in their portfolio should check whether that document affects their own compliance files, since the records do not link it to the gestodene outcome.

Medical device vigilance runs on a separate track. The AEMPS warning on certain Likorall ceiling patient lifts and the Helena Laboratories field safety notice published via the Dutch inspectorate IGJ are examples. They matter for organisations that handle both medicines and devices, but they are governed by different rules and should not be mixed into medicinal product safety reporting.

What to watch

First, read the full published outcome and product list for any wording changes, and check whether implementation timelines apply. The record does not state any.

Second, watch for national implementation of the result across Member States, particularly for products authorised only nationally.

Third, follow the Duvyzat review in the UK. Whether its outcome extends beyond the UK is not yet known from the records, and any wider EU action would be a separate process.

Finally, the PPI plan the MHRA published for 2026-2030 shows regulators placing more weight on patient and public involvement in their decisions. The record does not say how this will change safety procedures, but PV teams should expect patient perspectives to feature more in regulatory discussions.